pharmaphorum

OCTOBER 12, 2021

A data-mining study conducted by researchers in the US has found that an already-approved diuretic drug could have potential as a treatment for some patients with Alzheimer’s disease. The results are strong enough to back a proof-of-concept study in people with genetic risk of Alzheimer’s according to the researchers.

Gene Expression 111

Gene Expression Drugs FDA Approval Gene 111

World of DTC Marketing

JANUARY 31, 2021

So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). Ex vivo (where cells are genetically modified outside the body) cell and gene therapies have generated considerable excitement on their potential to cure previously incurable diseases.

In-Vivo 187

In-Vivo Generic Drugs Drugs Gene Therapy 187

XTalks

FEBRUARY 5, 2024

Alecensa is approved in Japan for the additional indication of recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma. Alecensa is not currently available in generic form. million the drug made during the same time in 2022. Price of Yescarta: Yescarta costs approximately $373,000 per treatment regimen.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

FEBRUARY 5, 2024

Alecensa is approved in Japan for the additional indication of recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma. Alecensa is not currently available in generic form. million the drug made during the same time in 2022. Price of Yescarta: Yescarta costs approximately $373,000 per treatment regimen.

FDA Approval 52

FDA Approval Drugs Sales Development 52

FDA Law Blog

OCTOBER 24, 2024

Gibbs — A recent blog post focused on the potentially negative implications of the proposed Patent Eligibility Restoration Act (PERA) for manufacturers of generic drugs and biosimilar products. By 2010, about 2000 isolated human genes had been patented in the U.S. animal, viral, bacterial) DNA and RNA sequences.

Gene 64

Gene DNA Genetics Gene Sequencing 64

XTalks

SEPTEMBER 14, 2020

CanSino Biologics is developing a vaccine that involves snipping a bit of the virus’ genetic code off and coupling it with a harmless virus to provoke a SARS-CoV-2 immune response. Several laboratories have already shown that they can detect genetic material from the virus in wastewater.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92